Making better commercial use of its US marketed portfolio and pipeline by licensing assets to international partners forms part of a major turnaround plan for Amneal Pharmaceuticals unveiled by co-CEOs Chirag and Chintu Patel three months after they resumed control following the departure in early August of former CEO Rob Stewart and executive chairman Paul Bisaro.
Other elements of the plan laid out by the Patel brothers, who founded Amneal in 2002 and grew it into...





